Tracer library / [225Ac]Ac-DOTA-TA99
[225Ac]Ac-DOTA-TA99
Also written as [Ac-225]Ac-DOTA-TA99
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 1
What it is
- Compound class
- Radiolabeled monoclonal antibody (DOTA-conjugated, anti-melanoma antigen TA99 mAb)
- Target / mechanism
- TA99 monoclonal antibody target antigen (melanoma-associated antigen, gp75/TYRP1) on murine melanoma cells PMID 40015918
- Clinical application
- Preclinical murine melanoma model of radiopharmaceutical therapy (alpha-RPT), studying immune-mediated response PMID 40015918
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | — | >90% | TA99-DOTA BioXCell | 40015918 2025 J Nucl Med the desired activity (9.25 or 18.5 kBq) was added to the reaction mixture (for a specific activity of 37 kBq/µg), and the solution was incubated at 40°C for 1 h |
Precursor
- Common precursor
- —
- Suppliers seen in the literature
- —
- Cited suppliers in indexed syntheses
- BioXCell
- Typical final purification
- —
Need this precursor?We can point you to suppliers for [225Ac]Ac-DOTA-TA99, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40015918. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40015918: 'TA99-DOTA (4.82 mg/mL; DOTA/mAb ratio, 2 ± 1) in 0.25 M ammonium acetate buffer (pH 7) was prepared.'. Stage set/updated at stage 39 from PMID 40015918: 'Preclinical and clinical studies increasingly show that the immune response plays a major role in radiotherapy.'.